Semaglutide News and Research

Latest Semaglutide News and Research

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Fewer than 1 in 5 adults with Type 2 diabetes in the U.S. are meeting targets to reduce heart disease risk. Fortunately, available therapies can help when combined with new approaches that address social determinants of health and other barriers to care, according to a new American Heart Association scientific statement published today in the Association's flagship journal Circulation.

10 Jan 2022

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

A little wiggle room might be just what the doctor ordered. New research suggests that the peptides -; short chunks of protein -; used to treat Type 2 diabetes may be more effective if they're able to flexibly move back and forth between different shapes.

23 Dec 2021

New study shows inequities in the use of heart disease-protective diabetes drug

A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status.

17 Dec 2021

Safer, more effective therapies could help fight the obesity epidemic

Novel obesity treatments such as modulation of the gut microbiome and gene therapy are underutilized and could help fight the obesity epidemic, according to a new manuscript published in the Endocrine Society's journal, Endocrine Reviews.

26 Oct 2021

Drug company pipelines are filling up with new molecules to help people lose weight

Drugs that promise to help people lose weight have had a checkered past, such as the infamous fen-phen that was pulled from the market in 1997 after reports of heart valve damage. But now, drug company pipelines are filling up with new molecules that aim to help people safely shed extra pounds, according to a cover story in Chemical & Engineering News, an independent news outlet of the American Chemical Society.

21 Oct 2021

Drugs and surgery show promise for reducing long-term effects of obesity-related hypertension

Weight-loss medications and surgical procedures show promise for reducing the long-term effects of high blood pressure (also called hypertension) in people who are overweight or have obesity, according to a new American Heart Association scientific statement published today in the Association's journal Hypertension.

20 Sep 2021

Popular class of diabetes medications may be protective against glaucoma

A popular class of diabetes medications called GLP-1R agonists (Trulicity and Rybelsus) may also protect against glaucoma in diabetic patients, according to a new study led by researchers in the Scheie Eye Institute at the University of Pennsylvania's Perelman School of Medicine.

20 Sep 2021

Improving lifestyle and medication use could add healthy years of life after a heart attack

Adherence to lifestyle advice and medications could add seven healthy years of life after a heart attack, according to a study presented at ESC Congress 2021.

26 Aug 2021

Diabetes drug’s new weight loss formula fuels cost-benefit debate

The long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people — especially those with Type 2 diabetes, which is associated with obesity — may desperately want.

30 Jul 2021

Study evaluates the difference in weight loss caused by two antidiabetic medications

Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study.

2 Jul 2021

Vegan protein shakes may be viable alternatives to milk-based whey protein shakes

A study from the Centre for Nutraceuticals at the University of Westminster found that plant-based protein shakes may be potential viable alternatives to milk-based whey protein shakes, particularly in people with need of careful monitoring of glucose levels.

24 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Asthma patients can benefit from type 2 diabetes medication

Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

21 May 2021

Researchers reveal how to effectively achieve and maintain a healthy weight loss

Almost one in five Danes live with obesity, which may have serious health consequences. In the world's most recognized medical journal, Danish researchers now document how to effectively achieve and maintain a healthy weight loss.

6 May 2021

Hopkins Medicine endocrinologist publishes first clinical practice review on diabetes management

New medicines for people who have diabetes seem to pop up all the time. Drugs that help the body break down carbohydrates, drugs that increase excretion of glucose in the urine, drugs that help muscles respond to insulin and drugs that stimulate the pancreas to produce it -; the list of pharmaceutical options to treat diabetes gets longer and longer.

7 Apr 2021

HCAs are a promising risk indicator of type 2 diabetes

A series of studies led by researchers from Hong Kong Baptist University have revealed that hyocholic acid and its derivatives (collectively known as HCAs), a component of bile acids that facilitate fat digestion, are a promising risk indicator of type 2 diabetes.

1 Apr 2021

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Bariatric surgery can significantly reduce the risk of cancer--and especially obesity-related cancers--by as much as half in certain individuals, according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

26 Mar 2021

Semaglutide News and Research

Latest Semaglutide News and Research

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

New study shows inequities in the use of heart disease-protective diabetes drug

Safer, more effective therapies could help fight the obesity epidemic

Drug company pipelines are filling up with new molecules to help people lose weight

Drugs and surgery show promise for reducing long-term effects of obesity-related hypertension

Popular class of diabetes medications may be protective against glaucoma

Improving lifestyle and medication use could add healthy years of life after a heart attack

Diabetes drug’s new weight loss formula fuels cost-benefit debate

Study evaluates the difference in weight loss caused by two antidiabetic medications

Vegan protein shakes may be viable alternatives to milk-based whey protein shakes

Weight loss drug Wegovy approved by FDA

Asthma patients can benefit from type 2 diabetes medication

Researchers reveal how to effectively achieve and maintain a healthy weight loss

Hopkins Medicine endocrinologist publishes first clinical practice review on diabetes management

HCAs are a promising risk indicator of type 2 diabetes

Bariatric surgery can reduce the risk of obesity-related cancers, study shows

Semaglutide drug also helps diabetic patients lose body weight, shows study

Study: Semaglutide drug promotes weight loss in patients with type 2 diabetes

Study shows reliability and robustness of injectable anti-obesity medication

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in